BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Investors in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) had a good week, as its shares rose 6.7% to close at US$68.73 following the release of its full-year results. BioMarin Pharmaceutical reported US$2.9b in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of US$2.21 beat expectations, being 9.6% higher than what the analysts expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Check out our latest analysis for BioMarin Pharmaceutical

Following the latest results, BioMarin Pharmaceutical's 26 analysts are now forecasting revenues of US$3.14b in 2025. This would be a meaningful 9.9% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to bounce 40% to US$3.14. Before this earnings report, the analysts had been forecasting revenues of US$3.10b and earnings per share (EPS) of US$2.96 in 2025. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.

The consensus price target was unchanged at US$96.56, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values BioMarin Pharmaceutical at US$126 per share, while the most bearish prices it at US$65.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We can infer from the latest estimates that forecasts expect a continuation of BioMarin Pharmaceutical'shistorical trends, as the 9.9% annualised revenue growth to the end of 2025 is roughly in line with the 9.6% annual growth over the past five years. Compare this with the broader industry (in aggregate), which analyst estimates suggest will see revenues grow 21% annually. So it's pretty clear that BioMarin Pharmaceutical is expected to grow slower than similar companies in the same industry.

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards BioMarin Pharmaceutical following these results. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for BioMarin Pharmaceutical going out to 2027, and you can see them free on our platform here..

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.